SCHEMBL2462942

SCHEMBL2462942

O=c1[nH]ncc2cc(Nc3ccccc3)c(NC3CCCCC3)cc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.44
▸ HSD17B10 Q99714 2/20 0.44
▸ TDP1 Q9NUW8 2/20 0.44
▸ KDM4E B2RXH2 2/20 0.44
▸ MAPT P10636 2/20 0.44
▸ MEN1 O00255 1/20 0.44
▸ APAF1 O14727 1/20 0.44
▸ MAPK1 P28482 1/20 0.44
▸ BLM P54132 1/20 0.44
▸ KMT2A Q03164 1/20 0.44
▸ HTR2A P28223 2/20 0.43
▸ HTR2C P28335 1/20 0.43
▸ NPY5R Q15761 1/20 0.42
▸ ELANE P08246 1/20 0.40
▸ ADORA2A P29274 4/20 0.40
▸ ADORA1 P30542 4/20 0.40
▸ ADORA3 P0DMS8 3/20 0.40
▸ CDC7 O00311 4/20 0.39
▸ DBF4 Q9UBU7 2/20 0.39
▸ ROCK2 O75116 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9413547 0.88 ALDH1A1 (0.48) ALDH1A1HSD17B10TDP1KDM4EMAPT
SCHEMBL2459339 0.86 ALDH1A1 (0.51) ALDH1A1HSD17B10TDP1KDM4EMAPT
SCHEMBL3691601 0.69 MAPT (0.58) ALDH1A1HSD17B10TDP1KDM4EMAPT
SCHEMBL11347783 0.69 MAPT (0.58) ALDH1A1HSD17B10TDP1KDM4EMAPT
SCHEMBL11356271 0.67 MAPT (0.55) ALDH1A1HSD17B10TDP1KDM4EMAPT
SCHEMBL39716 0.66 MAPT (0.58) ALDH1A1HSD17B10TDP1KDM4EMAPT
SCHEMBL809612 0.66 MAPT (0.58) ALDH1A1HSD17B10TDP1KDM4EMAPT
SCHEMBL809549 0.66 MAPT (0.58) ALDH1A1HSD17B10TDP1KDM4EMAPT
SCHEMBL11356806 0.66 MAPT (0.58) ALDH1A1HSD17B10TDP1KDM4EMAPT
SCHEMBL1848681 0.66 MAPT (0.58) ALDH1A1HSD17B10TDP1KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8044041-B2 e.g. 4-Chloro-1-hydroxy-phthalazine-6-carboxylic acid [4-chloro-3'-(2-dimethylamino-ethoxy)-biphenyl-3-yl]-amide; multifunctioning protein kinase inhibitors; anticarcinogenic, antiinflammatory, antidiabetic agent, neurodegenerative diseases FOREST LABORATORIES HOLDINGS LIMITED (BM) 2011-10-25 — — US claimed
US-20080146547-A1 PHTHALAZINE DERIVATIVES FOREST LABORATORIES HOLDINGS LIMITED (BM) 2008-06-19 — — US claimed
EP-0600831-A1 Phtalazinon derivatives CIBA-GEIGY AG (CH) 1994-06-08 — — EP claimed
US-8349836-B2 Phthalazine derivatives as inhibitors of protein kinase ARALDI GIAN-LUCA (US) 2013-01-08 — — US disclosed
US-8044041-B2 e.g. 4-Chloro-1-hydroxy-phthalazine-6-carboxylic acid [4-chloro-3'-(2-dimethylamino-ethoxy)-biphenyl-3-yl]-amide; multifunctioning protein kinase inhibitors; anticarcinogenic, antiinflammatory, antidiabetic agent, neurodegenerative diseases FOREST LABORATORIES HOLDINGS LIMITED (BM) 2011-10-25 — — US disclosed
US-20110237571-A1 PHTHALAZINE DERIVATIVES ARALDI GIAN-LUCA 2011-09-29 — — US disclosed
US-7432263-B2 Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them PFIZER ITALIA, S.R.L. (IT) 2008-10-07 — — US disclosed
EP-1427708-B1 AMINO-PHTHALAZINONE DERIVATIVES AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM PFIZER ITALIA SRL (IT) 2008-09-10 — — EP disclosed
US-20080146547-A1 PHTHALAZINE DERIVATIVES FOREST LABORATORIES HOLDINGS LIMITED (BM) 2008-06-19 — — US disclosed
US-20050020583-A1 Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them PFIZER ITALIA S.R.L. (IT) 2005-01-27 — — US disclosed
US-20030073692-A1 Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them PHARMACIA & UPJOHN S.P.A. (IT) 2003-04-17 — — US disclosed
EP-0600831-A1 Phtalazinon derivatives CIBA-GEIGY AG (CH) 1994-06-08 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237571-A1 PHTHALAZINE DERIVATIVES CDK5, HIPK2, PACSIN2 ALDH1A1 3613/4885HSD17B10 2331/4885TDP1 2485/4885
US-20030073692-A1 Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them MAP3K20, MAP3K15, MAP3K5 ALDH1A1 4569/4885HSD17B10 3268/4885TDP1 1215/4885
US-20080146547-A1 PHTHALAZINE DERIVATIVES CDK5, HIPK2, PACSIN2 ALDH1A1 3613/4885HSD17B10 2331/4885TDP1 2485/4885
US-20050020583-A1 Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them MAP3K20, MAP3K1, MAP3K15 ALDH1A1 3566/4885HSD17B10 3121/4885TDP1 819/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback